Pharma News

Numidargistat by Calithera Biosciences for Head And Neck Cancer Squamous Cell Carcinoma: Likelihood of Approval

Numidargistat is under clinical development by Calithera Biosciences and currently in Phase II for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Head And Neck Cancer Squamous Cell Carcinoma have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Numidargistat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Numidargistat overview

Numidargistat (INCB-01158 (CB-1158)) is under development for the treatment of  solid tumors such as breast cancer, bladder cancer, malignant mesothelioma, relapsed or refractory multiple myeloma, melanoma, including renal cell carcinoma, non-small cell lung cancer, colorectal cancer, head and neck cancer squamous cell carcinoma, adenocarcinoma of the gastroesophageal junction, epithelial ovarian, peritoneal, or fallopian tube carcinoma, adenocarcinoma, carcinosarcomas and biliary tract cancer, small cell-lung cancer and urothelial cell cancer. It is a small molecule administered orally in the form of capsule. It acts by targeting the enzyme arginase 1 and 2.

Calithera Biosciences overview

Calithera Biosciences (Calithera) is a clinical-stage bio-pharmaceutical company that discovers and develops novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company’s product pipeline includes CB-839, a glutaminase inhibitor in tumor metabolism to treat solid tumors, NCB001158, a small molecule arginase inhibitor based on tumor immunology technology that activates the body’s own immune system to attack and kill cancer cells for the treatment of hematology and oncology diseases, CB-280, a arginase inhibitor used for treating Cystic Fibrosis, CB-708, a CD73 inhibitor against immuno-oncology conditions and IL4I1 Inhibitor CB-668 against immuno-oncology conditions. The company works in collaboration with bio-pharmaceutical companies such as Incyte Corp, Bristol-Myers Squibb (BMS), and Mars Symbiosciences Inc. Calithera is headquartered in South San Francisco, California, the US.

For a complete picture of Numidargistat’s drug-specific PTSR and LoA scores, buy the report here.

Source link
#Numidargistat #Calithera #Biosciences #Neck #Cancer #Squamous #Cell #Carcinoma #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *